Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
12,13 Multiple clinical trials have been launched to therapeutically target key oncogenic signaling pathways in drug-resistant cancers, underscoring the translational relevance of this axis (Table 2)
Single agent, canfosfamide (C, TLK286) vs pegylated liposomal doxorubicin (D) or topotecan (T) in 3rd-line treatment of platinum (P) refractory or resistant ovarian cancer (OC): phase 3 study results [Abstract]
You're tired of managing instead of healing
Wilsons disease or other disorders of copper metabolism
Hansen et al
US$ 22.54
US$ 27.97
US$ 29.64
US$ 23.54
US$ 25.86
US$ 29.68
US$ 21.84
